研報掘金丨方正證券:恒瑞醫藥上半年業績超預期,維持“強烈推薦”評級
方正證券研報指出,恒瑞醫藥(600276.SH)2024年H1業績超越預期,創新成果臨牀價值凸顯+出海雙驅動業績增長。維持“強烈推薦”評級。上半年公司創新藥收入達66.12億元(含税,不含對外許可收入),雖然面臨競爭加劇、產品降價及准入難等因素影響,仍然實現了同比33%的增長。創新藥出海取得成效,成為業績增長的第二引擎。報吿期內,公司已將收到的 Merck Healthcare 1.6億歐元對外許可首付款確認為收入,進一步推動經營業績指標增長。綜合來看,恒瑞醫藥的2024年中報業績顯示出公司在創新驅動和國際化戰略下的穩健發展態勢,創新藥物的快速增長和研發投入的增加為公司的長期發展奠定了堅實基礎。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.